Screener
Alnylam Pharmaceuticals ALNY Preferred Stock Par Value Per Share
Preferred Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 4,204,651 | 4,177,155 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025 | 1,337 | 1,324 |
| Additional paid-in capital | 7,716,958 | 7,510,473 |
| Accumulated other comprehensive loss | (32,138) | (20,097) |
| Accumulated deficit | (6,332,039) | (6,702,524) |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's preferred stock par value per share?
- Alnylam Pharmaceuticals (ALNY) reported preferred stock par value per share of $0.01 in Q2 2026.
- How has Alnylam Pharmaceuticals's preferred stock par value per share changed year-over-year?
- Alnylam Pharmaceuticals's preferred stock par value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
- What is the long-term trend for Alnylam Pharmaceuticals's preferred stock par value per share?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's preferred stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.
- What does preferred stock par value per share mean?
- The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.
Ask your AI about Alnylam Pharmaceuticals's preferred stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude